X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Iran Expo
Not Confirmed
Contact Supplier
Details:
Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Elores
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin® (ceftriaxone sodium), a long-acting, broad spectrum cephalosporin antibiotic, including the product's marketing authorization and certain intellectual property, including trademarks.
Lead Product(s): Ceftriaxone
Therapeutic Area: Infections and Infectious Diseases Product Name: Rocephin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hasten Biopharmaceutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
